Skip to content

MSUD Gene Therapy Shows Promise in Animal Trials

3 March 20251 min read
SCIENCE & TECHNOLOGYMSUD GeneTherapy ShowsPromise in AnimalTrials3 March 2025safalsetu.com

Why in the news

A gene replacement therapy for Maple Syrup Urine Disease (MSUD) gave promising results in animals.

Key facts

  • The vector is an adeno-associated virus carrying BCKDHA and BCKDHB genes.
  • Treated animals avoided the fatal neurological signs; the therapy was active in knockout cells, safe in wild-type mice and prevented deaths in deficient mice.
  • Untreated MSUD cases cannot shift to a high-protein diet; the treated calf could.

Significance

  • Patients now rely on a strict low-protein diet or a liver transplant.
  • Gene therapy may offer a less invasive, lasting option; next, study BCKDH levels in the brain and long-term cognitive effects.

Exam angle

  • Genes: BCKDHA, BCKDHB.
  • Vector: adeno-associated virus.

Test yourself

1. In the MSUD gene therapy research, which vector carried the working genes into cells?

The therapy used an adeno-associated viral vector to deliver BCKDHA and BCKDHB genes.

2. Which pair of genes is delivered by the gene therapy for Maple Syrup Urine Disease?

Functional copies of BCKDHA and BCKDHB are supplied by the therapy.

3. What is the characteristic sign of Maple Syrup Urine Disease?

Failure to process certain amino acids gives urine a maple-syrup smell.